Biocryst Pharmaceuticals (BCRX) Cash from Investing Activities Growth (3y) (2013 - 2026)
Biocryst Pharmaceuticals (BCRX) Cash from Investing Activities Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.92 Bn | 42.96 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.53 Bn | 2.15 Bn | -53.63% |
| 3 | Zoetis | 31.74 Bn | 30.06 Bn | 1.05 Bn | -55.36% |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.87 Bn | 5.10 Bn | 34.35% |
| 5 | United Therapeutics | 22.22 Bn | 19.56 Bn | 683.80 Mn | 33.61% |
| 6 | Viatris | 18.71 Bn | 17.83 Bn | 1.46 Bn | 15.92% |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | -2.45% |
| 8 | Elanco Animal Health | 11.80 Bn | 11.27 Bn | 798.00 Mn | -36.76% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Biocryst Pharmaceuticals | 2.46 Bn | 2.11 Bn | 214.41 Mn | -79.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -79.53% |
| Mar 31, 2026 | -35.87% |
| Dec 31, 2025 | -45.52% |
| Sep 30, 2025 | 29.96% |
| Jun 30, 2025 | 31.98% |
| Mar 31, 2025 | 39.32% |
| Dec 31, 2024 | 53.27% |
| Sep 30, 2024 | 3.10% |
| Jun 30, 2024 | -36.51% |
| Mar 31, 2024 | 25.14% |
| Dec 31, 2023 | -49.33% |
| Sep 30, 2023 | 38.88% |
| Jun 30, 2023 | -56.86% |
| Mar 31, 2023 | -128.87% |
| Dec 31, 2022 | 68.08% |
| Sep 30, 2022 | -70.51% |
| Jun 30, 2022 | -85.41% |
| Mar 31, 2022 | -64.14% |
| Dec 31, 2021 | -51.99% |
| Sep 30, 2021 | 41.17% |